Core Viewpoint - The report titled "2025-2031 China Vaccine Industry Investment Strategy Discussion and Market Size Forecast" aims to provide high-quality, professional industry analysis to guide strategic planning, market expansion, and investment decisions in the vaccine sector [1][2]. Group 1: Industry Overview - The vaccine industry is a critical component of public health systems, directly impacting national health and social stability, and is a key indicator of a country's biopharmaceutical competitiveness [4]. - The Chinese vaccine industry is experiencing rapid growth, with the market size projected to increase from 30.622 billion yuan in 2015 to 176.219 billion yuan in 2024, and expected to exceed 300 billion yuan by 2031 [4]. Group 2: Market Dynamics - The vaccine industry supply chain consists of upstream raw material suppliers, midstream product development and manufacturing, and downstream distribution to end consumers [7]. - The competitive landscape features a diverse market with local companies rising, foreign firms deepening their presence, and new entrants joining the market. Major foreign players like Merck, Pfizer, and GlaxoSmithKline hold significant positions in the high-end vaccine market [10]. - Local companies such as China National Pharmaceutical Group, Zhifei Biological Products, and Watson Biotech are leveraging technological advancements and policy support to gain market share from foreign competitors [10][11]. Group 3: Research Methodology - The report employs a combination of quantitative analysis and qualitative interviews to ensure data accuracy while capturing subtle market dynamics [1][2]. - Data sources include primary research through interviews with industry executives and secondary data from government agencies, industry associations, and publicly available reports [15]. Group 4: Future Outlook - The report emphasizes the importance of understanding market trends and dynamics for stakeholders, including corporate decision-makers and market analysts, to navigate the complex and evolving vaccine market [14].

Industry Overview - Vaccines are essential biological products for preventing and controlling infectious diseases, representing a core defense in public health systems [1][5] - The Chinese vaccine industry is experiencing rapid growth, with the market size projected to increase from 306.22 billion yuan in 2015 to 1,762.19 billion yuan in 2024, and expected to exceed 300 billion yuan by 2031 [1][5] Industry Chain - The upstream of the vaccine industry includes raw material supply, such as microcarriers, human serum albumin, and packaging materials [3] - The midstream involves vaccine research and production, with key players including Sinopharm, Sinovac, CanSino, Zhifei, and Watson [3] - The downstream consists of vaccine distribution and consumption, reaching end consumers through health service centers and medical institutions [3] Current Industry Status - As of December 31, 2024, 47 companies in China have received vaccine batch approvals, totaling 543 million doses, with a decrease of 5.6% compared to 2023 [7] - The most approved vaccines in 2024 were influenza and rabies vaccines, each exceeding 80 million doses, accounting for 30% of total approvals [9] Market Competition - The Chinese vaccine market is characterized by a diverse competitive landscape, with local companies like Sinopharm and Zhifei rising against foreign giants like Merck and Pfizer [11] - Zhifei has achieved significant growth in international markets, with a 300% increase in exports of its WHO-precertified 23-valent pneumococcal polysaccharide vaccine [11] - Innovative companies like CanSino and Watson are making breakthroughs in mRNA and recombinant protein vaccines, enhancing their market presence [11][12] Future Trends - Technological innovation is driving the vaccine industry forward, with new platforms like mRNA and gene-engineered vaccines emerging [17] - The adult vaccine market is growing, with a 45% increase in HPV vaccine uptake in 2024, indicating a shift in public health awareness [18] - Chinese vaccine companies are expanding internationally, with over 2.5 billion doses of COVID-19 vaccines supplied abroad, focusing on markets in Africa and Southeast Asia [19]